Hydralazine target: From blood vessels to the epigenome
2006

Hydralazine: From Blood Vessels to Cancer Treatment

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): Claudia Arce, Blanca Segura-Pacheco, Enrique Perez-Cardenas, Lucia Taja-Chayeb, Myrna Candelaria, Alfonso Duenas-Gonzalez

Primary Institution: Instituto Nacional de Cancerología, Mexico City, Mexico

Hypothesis

Can hydralazine, a drug used for hypertension, be effective in demethylating tumor suppressor genes in cancer treatment?

Conclusion

Hydralazine has shown potential to demethylate and reactivate tumor suppressor genes in cancer patients.

Supporting Evidence

  • Hydralazine has been used for decades, showing clinical safety and tolerability.
  • 70% of patients had at least one methylated gene before treatment.
  • Post-treatment biopsies showed variable demethylation rates for different genes.

Takeaway

Hydralazine, a medicine for high blood pressure, might help fight cancer by turning back on genes that stop tumors from growing.

Methodology

The study involved a phase I trial where patients with cervical cancer received hydralazine to assess its effects on gene methylation.

Limitations

The study had a small sample size and focused only on cervical cancer.

Participant Demographics

Patients were newly diagnosed with locally advanced cervical cancer.

Digital Object Identifier (DOI)

10.1186/1479-5876-4-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication